Future of ToxicologyIron Chelators and Differing Modes of Action and Toxicity: The Changing Face of Iron Chelation Therapy
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Iron (Fe) chelation therapy was initially designed to alleviate the toxic effects of excess Fe evident in Fe-overload diseases. However, the novel toxicological properties of some Fe chelator-metal complexes have shifted appreciable focus to their application in cancer chemotherapy. Redox-inactive Fe chelator complexes are well suited for the treatment of Fe-overload diseases, whereas Fe chelator complexes with high redox activity have shown promising results as chemotherapeutics against cancer. Within this perspective, we discuss the different modes of action and toxicological profiles of Fe chelators, including analogues of 2-pyridylcarboxaldehyde isonicotinoyl hydrazone, di-2-pyridylketone isonicotinoyl hydrazone, di-2-pyridylketone thiosemicarbazone, and the clinically trialed chelator 3-aminopyridine-2-carboxaldehyde thiosemicarbazone. The potential application of these agents in the changing face of Fe chelation therapy is discussed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Kalinowski and Richardson have recently reviewed synthetic chelators based on various chelating chemical groupings such as catechol, hydroxamate, and hydroxypyridinone, concluding that structures providing hexadentate hydroxypyridinone functionality (an example being deferiprone) have particular promise as bacteriostatic agents in relation to outcompeting siderophores of microbes [49].”
From The utility of iron chelators in the management of inflammatory disorders (2015) · cites this paper as [49]
Citations
Cites
Free Radicals in Biology and Medicine
Land, E. T. (1990) · International Journal of Radiation Biology · doi:10.1080/09553009014552071 · Cited by 4,854
Neurodegenerative diseases and oxidative stress
Barnham, K. J., Masters, C. L., & Bush, A. I. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1330 · Cited by 3,683
Thelander, L., & Reichard, P. (1979) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.48.070179.001025 · Cited by 1,167
The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer
Kalinowski, D. S., & Richardson, D. R. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.4.2 · Cited by 721
Self-citationRichardson, D. R., Sharpe, P. C., Lovejoy, D. B., Senaratne, D., Kalinowski, D. S., Islam, M., & Bernhardt, P. V. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0606342 · Cited by 383
Self-citationLe, N. T. V., & Richardson, D. R. (2004) · Blood · doi:10.1182/blood-2004-05-1866 · Cited by 321
Self-citationFinch, R. A., Liu, M.-C., Cory, A. H., Cory, J. G., & Sartorelli, A. C. (1999) · Advances in Enzyme Regulation · doi:10.1016/s0065-2571(98)00017-x · Cited by 223
Chaston, T. B., Lovejoy, D. B., Watts, R., & Richardson, D. R. (2003) · PubMed · Cited by 221
Self-citationChelators at the cancer coalface: Desferrioxamine to Triapine and beyond
Yu, Y., Wong, J., Lovejoy, D. B., Kalinowski, D. S., & Richardson, D. R. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1954 · Cited by 195
Self-citationWadler, S., Makower, D., Clairmont, C., Lambert, P., Fehn, K., & Sznol, M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.158 · Cited by 139
Research works printed but not linked: 28
- Liu Z. D., 2002, Med. Res. Rev., 22, 64
- Lovejoy D. B., 2000, Complexes of gallium(III) and other metal ions and their potential in the treatment of neoplasia. Expert Opin. Invest. Drugs 9, 1257−1270
- Olivieri N. F., 1997, Iron-chelating therapy and the treatment of thalassemia. Blood 89, 739−761
- Wong A., 1999, The Friedreich's ataxia mutation confers cellular sensitivity to oxidant stress which is rescued by chelators of iron and calcium and inhibitors of apoptosis. Hum. Mol. Genet. 8, 425−430
- Shinar E., 1990, Semin. Hematol., 27, 82
- Kolberg M., 2004, Biochim. Biophys. Acta, 1699, 34
- Thelander L., 1983, Continual presence of oxygen and iron required for mammalian ribonucleotide reduction: possible regulation mechanism. Biochem. Biophys. Res. Commun. 110, 859−865
- Gao J., 2001, IV: The mechanisms involved in inhibiting cell-cycle progression. Blood 98, 842−850.
- Nurtjahja-Tjendraputra E., 2006, Iron chelation regulates cyclin D1 expression via the proteasome: a link to iron deficiency-mediated growth suppression. Blood, in press
- Armstrong C. M., 2003, Eur. J. Inorg. Chem., 2003
- Wong C. S., 2004, Biochim. Biophys. Acta, 1739, 80
- Richardson D. R., 2001, Biochim. Biophys. Acta, 1536
- Chaston T. B., 2004, Potent antitumor activity of novel iron chelators derived from di-2-pyridylketone isonicotinoyl hydrazone involves fenton-derived free radical generation. Clin. Cancer Res. 10, 7365−7374
- Sartorelli A. C., 1971, Mechanism of inhibition of ribonucleoside diphosphate reductase by α-(N)-heterocyclic aldehyde thiosemicarbazones. Biochem. Pharmacol. 20, 3119−3123
- Sartorelli A. C., 1967, Inhibition of the growth of sarcoma 180 ascites cells by combinations of inhibitors of nucleic acid biosynthesis and the cupric chelate of kethoxal bis-(thiosemicarbazone). Cancer Res. 27, 1614−1619
- Agrawal K. C., 1978, The chemistry and biological activity of α-(N)-heterocyclic carboxaldehyde thiosemicarbazones. Prog. Med. Chem. 15, 321−356
- Yuan J., 2004, Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood 104, 1450−1458
- Whitnall M., 2006, Proc. Natl. Acad. Sci. U.S.A. 103
- Shao J., 2006, A Ferrous-Triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase. Mol. Cancer. Ther. 5, 586−592
- Cory J. G., 1994, Inhibitors of ribonucleotide reductase: Comparative effects of amino- and hydroxy-substituted pyridine-2-carboxaldehyde thiosemicarbazones. Biochem. Pharmacol. 48, 335−344
- Finch R. A., 2000, Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone): a potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. Biochem. Pharmacol. 59, 983−991
- Shao J., 2004, Cancer Res., 64, 6
- Cooper C. E., 1996, J. Biol. Chem., 271
- Chen C. H., 2002, Eur. J. Cancer, 38, S26
- Yen Y., 2004, A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer. Cancer Chemother. Pharmacol. 54, 331−342
- Liu Z. D., 2002, Coord. Chem. Rev., 232
- Richardson D. R., 1995, The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood 86, 4295−4306
- Abbreviations AP, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone
Cited by
Essential metals in health and disease
Jomova, K., Makova, M., Alomar, S. Y., Alwasel, S. H., Nepovimova, E., Kuca, K., Rhodes, C. J., & Valko, M. (2022) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2022.110173 · Cited by 1,121
Redox-Directed Cancer Therapeutics: Molecular Mechanisms and Opportunities
Wondrak, G. T. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2541 · Cited by 462
Yu, Y., Kalinowski, D. S., Kovacevic, Z., Siafakas, A. R., Jansson, P. J., Stefani, C., Lovejoy, D. B., Sharpe, P. C., Bernhardt, P. V., & Richardson, D. R. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900552r · Cited by 397
Self-citationLignin-derivatives based polymers, blends and composites: A review
Naseem, A., Tabasum, S., Zia, K. M., Zuber, M., Ali, M., & Noreen, A. (2016) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2016.08.030 · Cited by 343
Allele-Specific p53 Mutant Reactivation
Yu, X., Vazquez, A., Levine, A. J., & Carpizo, D. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.03.042 · Cited by 319
“Thiosemicarbazone:Fe complexes cause oxidative stress by the creation of hydroxyl radicals through Fenton chemistry (Kalinowski and Richardson, 2007; Richardson et al., 2006, 2009).”
Jiao, Y., Wilkinson, J., Di, X., Wang, W., Hatcher, H., Kock, N. D., D'Agostino, R., Knovich, M. A., Torti, F. M., & Torti, S. V. (2009) · Blood · doi:10.1182/blood-2008-05-155952 · Cited by 266
Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents
Richardson, D. R., Kalinowski, D. S., Lau, S., Jansson, P. J., & Lovejoy, D. B. (2009) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2008.04.003 · Cited by 258
“In contrast, Fe-depletionmediated by the chelator, 2,2- dipyridyl, was found to cause a 3-fold elevation in MMP-9 protein expression in HT1080 human fibrosarcoma cells [159].”
BackgroundInfluentialSelf-citationJansson, P. J., Sharpe, P. C., Bernhardt, P. V., & Richardson, D. R. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100561b · Cited by 243
Self-citationRedox active metal-induced oxidative stress in biological systems
Jomova, K., Baros, S., & Valko, M. (2012) · Transition Metal Chemistry · doi:10.1007/s11243-012-9583-6 · Cited by 240
Kalinowski, D. S., Yu, Sharpe, P. C., Islam, M., Liao, Y.-T., Lovejoy, D. B., Kumar, N., Bernhardt, P. V., & Richardson, D. R. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070445z · Cited by 222
Self-citationIron and Reactive Oxygen Species: Friends or Foes of Cancer Cells?
Bystrom, L. M., Guzman, M. L., & Rivella, S. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.5014 · Cited by 212
“Iron chelators are best known for their ability to sequester iron away from the cell or organism and to function as an antioxidant by preventing the Fenton reaction (17, 22).”
InfluentialHeffeter, P., Pape, V. F. S., Enyedy, É. A., Keppler, B. K., Szakacs, G., & Kowol, C. R. (2019) · Antioxidants & Redox Signaling · doi:10.1089/ars.2017.7487 · Cited by 202
Thiosemicarbazones: The New Wave in Cancer Treatment
Kalinowski, D. S., Quach, P., & Richardson, D. R. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.80 · Cited by 198
Self-citationNovel Chelators for Cancer Treatment: Where Are We Now?
Merlot, A. M., Kalinowski, D. S., & Richardson, D. R. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4540 · Cited by 185
Self-citationRecent progress in chemosensors based on pyrazole derivatives
Tigreros, A., & Portilla, J. (2020) · RSC Advances · doi:10.1039/d0ra02394a · Cited by 179
Redox Interactions of Vitamin C and Iron: Inhibition of the Pro-Oxidant Activity by Deferiprone
Timoshnikov, V. A., Kobzeva, T. V., Polyakov, N. E., & Kontoghiorghes, G. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113967 · Cited by 177
Bernhardt, P. V., Sharpe, P. C., Islam, M., Lovejoy, D. B., Kalinowski, D. S., & Richardson, D. R. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801012z · Cited by 166
Self-citationIron chelating agents for the treatment of iron overload
Crisponi, G., & Remelli, M. (2008) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2007.12.014 · Cited by 166
Jansson, P. J., Kalinowski, D. S., Lane, D. J. R., Kovačević, Ž., Seebacher, N. A., Fouani, L., Sahni, S., Merlot, A. M., & Richardson, D. R. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.08.013 · Cited by 152
Self-citationThiosemicarbazones as Potent Anticancer Agents and their Modes of Action
Shakya, B., & Yadav, P. N. (2019) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557519666191029130310 · Cited by 147
Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer
Nygren, P., Fryknäs, M., Ågerup, B., & Larsson, R. (2013) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-013-1539-5 · Cited by 133
“ROS generation could lead to several toxicological consequences as a result of oxidative injury to important biomolecules such as DNA, proteins and lipids (Kalinowski and Richardson 2007).”
BackgroundKontoghiorghes, G. J., Kolnagou, A., Kontoghiorghe, C., Mourouzidis, L., Timoshnikov, V. A., & Polyakov, N. E. (2020) · Medicines · doi:10.3390/medicines7080045 · Cited by 124
Jo, T. G., Bok, K. H., Han, J., Lim, M. H., & Kim, C. (2016) · Dyes and Pigments · doi:10.1016/j.dyepig.2016.11.052 · Cited by 108
Kalinowski, D. S., Sharpe, P. C., Bernhardt, P. V., & Richardson, D. R. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm7012562 · Cited by 113
Self-citationSahni, S., Bae, D.-H., Lane, D. J. R., Kovacevic, Z., Kalinowski, D. S., Jansson, P. J., & Richardson, D. R. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.529511 · Cited by 101
“This process occurs through an interaction between NDRG1 and the PERK/eIF2 axis and is evident for a variety of stress stimuli, including iron-deprivation, ROS generation, tunicamycin treatment, and serum starvation.”
BackgroundMethodInfluentialSelf-citationKalinowski, D. S., Sharpe, P. C., Bernhardt, P. V., & Richardson, D. R. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070839q · Cited by 98
Self-citationRainey, N. E., Moustapha, A., Šarić, A., Nicolas, G., Sureau, F., & Petit, P. X. (2019) · Cell Death Discovery · doi:10.1038/s41420-019-0234-y · Cited by 98
Advances in iron chelation: an update
Heli, H., Mirtorabi, S., & Karimian, K. (2011) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2011.569493 · Cited by 102
“Redox potential of various chelators has been shown to play a role in their inhibitory activity [290,293] and while redox inactive chelator complexes are suitable for the treatment of iron overload conditions, redox active complex are better suited for ribonucleotide reductase inhibition [294].”
BackgroundCancer cells with irons in the fire
Bystrom, L. M., & Rivella, S. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.04.035 · Cited by 89
Antitumor activity and mechanism of action of the iron chelator, Dp44mT, against leukemic cells
Noulsri, E., Richardson, D. R., Lerdwana, S., Fucharoen, S., Yamagishi, T., Kalinowski, D. S., & Pattanapanyasat, K. (2009) · American Journal of Hematology · doi:10.1002/ajh.21350 · Cited by 89
“, DNA synthesis) and the second punch is mediated by the generation of cytotoxic reactive oxygen species [37].”
BackgroundSelf-citationChellan, P., Shunmoogam‐Gounden, N., Hendricks, D. T., Gut, J., Rosenthal, P. J., Lategan, C. A., Smith, P. J., Chibale, K., & Smith, G. S. (2010) · European Journal of Inorganic Chemistry · doi:10.1002/ejic.201000317 · Cited by 84
He, L., Liu, C., & Xin, J. (2015) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2015.02.060 · Cited by 78
David, C. I., Bhuvanesh, N., Jayaraj, H., Thamilselvan, A., devi, D. P., Angamuthu, A., Prabhu, J., & Nandhakumar, R. (2020) · ACS Omega · doi:10.1021/acsomega.9b04294 · Cited by 82
Nurchi, V. M., Pivetta, T., Lachowicz, J. I., & Crisponi, G. (2008) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2008.10.011 · Cited by 87
Opletalová, V., Kalinowski, D. S., Vejsová, M., Kuneš, J., Pour, M., Jampílek, J., Buchta, V., & Richardson, D. R. (2008) · Chemical Research in Toxicology · doi:10.1021/tx800182k · Cited by 87
Self-citationLiao, Z., Liu, Y., Han, S.-F., Wang, D., Zheng, J., Zheng, X., & Jin, L. (2017) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2017.01.074 · Cited by 74
Bendova, P., Mackova, E., Haskova, P., Vavrova, A., Jirkovsky, E., Sterba, M., Popelova, O., Kalinowski, D. S., Kovarikova, P., Vavrova, K., et al. (2010) · Chemical Research in Toxicology · doi:10.1021/tx100125t · Cited by 73
Self-citationThe iron complex of Dp44mT is redox-active and induces hydroxyl radical formation: An EPR study
Jansson, P. J., Hawkins, C. L., Lovejoy, D. B., & Richardson, D. R. (2010) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2010.07.012 · Cited by 78
Self-citationXu, L., Mao, W. B., Huang, J., Li, S., Huang, K., Li, M., Xia, J., & Chen, Q. (2015) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2015.12.043 · Cited by 71
Luo, A., Wang, H., Wang, Y., Huang, Q., & Zhang, Q. (2016) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2016.05.048 · Cited by 68
Kaplánek, R., Havlík, M., Dolenský, B., Rak, J., Džubák, P., Konečný, P., Hajdúch, M., Králová, J., & Král, V. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.01.029 · Cited by 61
Stefani, C., Punnia-Moorthy, G., Lovejoy, D. B., Jansson, P. J., Kalinowski, D. S., Sharpe, P. C., Bernhardt, P. V., & Richardson, D. R. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200924c · Cited by 65
Self-citationSun, T., Niu, Q., Li, Y., Li, T., & Liu, H. (2017) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2017.03.128 · Cited by 60
Benzene's toxicity: a consolidated short review of human and animal studies by HA Khan
Snyder, R. (2007) · Human & Experimental Toxicology · doi:10.1177/0960327107083975 · Cited by 57
Kaplánek, R., Jakubek, M., Rak, J., Kejík, Z., Havlík, M., Dolenský, B., Frydrych, I., Hajdúch, M., Kolář, M., Bogdanová, K., et al. (2015) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2015.03.003 · Cited by 57
The utility of iron chelators in the management of inflammatory disorders
Lehmann, C., Islam, S., Jarosch, S., Zhou, J., Hoskin, D., Greenshields, A., Al-Banna, N., Sharawy, N., Sczcesniak, A., Kelly, M., et al. (2015) · Mediators of Inflammation · doi:10.1155/2015/516740 · Cited by 54
“Kalinowski and Richardson have recently reviewed synthetic chelators based on various chelating chemical groupings such as catechol, hydroxamate, and hydroxypyridinone, concluding that structures providing hexadentate hydroxypyridinone functionality (an example being deferiprone) have particular promise as bacteriosta…”
BackgroundLiu, Y., Li, A., Shao, J., Xie, C., Song, X., Bao, W.-G., & Xu, J. (2016) · Dalton Transactions · doi:10.1039/c6dt00451b · Cited by 57
Chelators in Iron and Copper Toxicity
Lawson, M. K., Valko, M., Cronin, M., & Jomová, K. (2016) · Current Pharmacology Reports · doi:10.1007/s40495-016-0068-8 · Cited by 62
The role of nutrition in influencing mechanisms involved in environmentally mediated diseases
Hennig, B., Petriello, M. C., Gamble, M. V., Surh, Y., Kresty, L. A., Frank, N., Rangkadilok, N., Ruchirawat, M., & Suk, W. A. (2018) · Reviews on Environmental Health · doi:10.1515/reveh-2017-0038 · Cited by 55
“The antioxidant properties of plant polyphenolics has been widely reported; yet, many of these constituents are redox reactive, forming iron complexes that result in cytotoxic cancer cell death due to the generation of reactive oxygen species (48, 49).”
BackgroundMenezes, S. V., Sahni, S., Kovačević, Ž., & Richardson, D. R. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.r117.776393 · Cited by 54
Self-citationLiu, J., Obando, D., Schipanski, L. G., Groebler, L. K., Witting, P. K., Kalinowski, D. S., Richardson, D. R., & Codd, R. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9016703 · Cited by 51
Self-citationOdenike, O. M., Larson, R. A., Gajria, D., Dolan, M. E., Delaney, S. M., Karrison, T. G., Ratain, M. J., & Stock, W. (2008) · Investigational New Drugs · doi:10.1007/s10637-008-9115-6 · Cited by 50
“Methemoglobinemia is a recognized complication of 3AP administration, and has been linked to the generation of reactive oxygen species [16, 17].”
BackgroundHe, Z., Huo, J., Gong, Y., An, Q., Zhang, X., Qiao, H., Yang, F., Zhang, X., Jiao, L.-M., Liu, H., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112970 · Cited by 56
p53 and Zinc: A Malleable Relationship
Ha, J., Prela, O., Carpizo, D. R., & Loh, S. N. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.895887 · Cited by 54
A Turn-on Fluorescent Iron Complex and Its Cellular Uptake
Chartres, J. D., Busby, M., Riley, M. J., Davis, J. J., & Bernhardt, P. V. (2011) · Inorganic Chemistry · doi:10.1021/ic201495r · Cited by 45
Stringer, T., Chellan, P., Therrien, B., Shunmoogam‐Gounden, N., Hendricks, D. T., & Smith, G. S. (2009) · Polyhedron · doi:10.1016/j.poly.2009.06.026 · Cited by 45
Zinc Metallochaperones as Mutant p53 Reactivators: A New Paradigm in Cancer Therapeutics
Kogan, S., & Carpizo, D. R. (2018) · Cancers · doi:10.3390/cancers10060166 · Cited by 47
“Thiosemicarbazones are known to chelate iron and cause oxidative stress by the production of hydroxyl radicals via Fenton chemistry [35].”
BackgroundPalanimuthu, D., Wu, Z., Jansson, P. J., Braidy, N., Bernhardt, P. V., Richardson, D. R., & Kalinowski, D. S. (2018) · Dalton Transactions · doi:10.1039/c8dt01099d · Cited by 44
Self-citationWijesinghe, T. P., Dharmasivam, M., Dai, C. C., & Richardson, D. R. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105889 · Cited by 39
Self-citationIron intake, red cell indicators of iron status, and DNA damage in young subjects
Prá, D., Bortoluzzi, A., Müller, L. L., Hermes, L., Horta, J. A., Maluf, S. W., Henriques, J. A. P., Fenech, M. F., & Franke, S. I. R. (2010) · Nutrition · doi:10.1016/j.nut.2010.02.001 · Cited by 41
Wang, Y., Man, Y., Li, S., Wu, S., Zhao, X., Xie, F., Qu, Q., & Zou, W. (2019) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2019.117594 · Cited by 38
The role of iron metabolism in cancer therapy focusing on tumor‐associated macrophages
Dong, D., Zhang, G., Yang, J., Zhao, B., Wang, S., Wang, L., Zhang, G., & Shang, P. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27569 · Cited by 41
“Iron chelators not only deplete cancer cells of iron, but also promote the redox cycling of iron to induce cytotoxic ROS production within tumors (Kalinowski & Richardson, 2007; Torti & Torti, 2013b).”
BackgroundSoni, S. (2020) · American Journal of Hematology · doi:10.1002/ajh.25909 · Cited by 42
“Restarting chelation post-treatment is also problematic, given the side effects of all the iron chelators.(96) The level of iron overload pre-transplant prior to SONI 1107”
BackgroundRepurposing an inhibitor of ribosomal biogenesis with broad anti-fungal activity
Sun, N., Li, D., Zhang, Y., Killeen, K., Groutas, W., & Calderone, R. (2017) · Scientific Reports · doi:10.1038/s41598-017-17147-x · Cited by 36
Investigation of the Biological Properties of (Hetero)Aromatic Thiosemicarbazones
Serda, M., Mrozek‐Wilczkiewicz, A., Jampílek, J., Peško, M., Kráľová, K., Vejsová, M., Musioł, R., Ratuszna, A., & Polański, J. (2012) · Molecules · doi:10.3390/molecules171113483 · Cited by 40
“More recently, iron chelators have been proposed for cancer treatment [5–10] because rapidly proliferating cancer cells have a higher demand for this element compared to the normal cells [5,11].”
BackgroundMyers, C. R. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.12.008 · Cited by 36
Kaya, B., Azad, M. G., Süleymanoğlu, M., Harmer, J. R., Wijesinghe, T. P., Richardson, V., Zhao, X., Bernhardt, P. V., Dharmasivam, M., & Richardson, D. R. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00884 · Cited by 35
Self-citationZhang, L., An, G., Yang, M., Li, M., & Zhu, X. (2012) · Inorganic Chemistry Communications · doi:10.1016/j.inoche.2012.02.009 · Cited by 35
Lukmantara, A. Y., Kalinowski, D. S., Kumar, N., & Richardson, D. R. (2014) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2014.07.020 · Cited by 38
Self-citationCarter, A., Racey, S. N., & Veuger, S. J. (2022) · Applied Sciences · doi:10.3390/app121910161 · Cited by 37
Dharmasivam, M., Kaya, B., Wijesinghe, T. P., Azad, M. G., Gonzálvez, M. A., Hussaini, M., Chekmarev, J., Bernhardt, P. V., & Richardson, D. R. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01600 · Cited by 35
Self-citationThe role of the NDRG1 in the pathogenesis and treatment of breast cancer
Zhao, X., & Richardson, D. R. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188871 · Cited by 39
Self-citationHuang, T., Sun, Y., Li, Y., Wang, T., Fu, Y., Li, C., & Li, C. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/4928703 · Cited by 36
Myers, J. M., Cheng, Q., Antholine, W. E., Kalyanaraman, B., Filipovska, A., Arnér, E. S. J., & Myers, C. R. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.02.016 · Cited by 31
“This is consistent with the observation that the potent Fe chelator deferoxamine, which stabilizes Fe(III) and thereby prevents Fe redox cycling and ROS generation [4], protects cells from Tp [7].”
BackgroundDrug-like chelating agents: a potential lead for Alzheimer's disease
Huang, W., Wei, W., & Shen, Z. (2014) · RSC Advances · doi:10.1039/c4ra09193k · Cited by 33
Mladěnka, P., Kalinowski, D. S., Hašková, P., Bobrovová, Z., Hrdina, R., Šimůnek, T., Nachtigal, P., Semecký, V., Vávrová, J., Holečková, M., et al. (2008) · Chemical Research in Toxicology · doi:10.1021/tx800331j · Cited by 29
Self-citationExploiting Cancer Metal Metabolism using Anti-Cancer Metal- Binding Agents
Merlot, A. M., Kalinowski, D. S., Kovačević, Ž., Jansson, P. J., Sahni, S., Huang, M., Lane, D. J. R., Lok, H. C., & Richardson, D. R. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867324666170705120809 · Cited by 31
Self-citationChelator-facilitated removal of iron from transferrin: relevance to combined chelation therapy
Ld, D., Evans, R. W., Evans, P., & Hider, R. C. (2007) · Biochemical Journal · doi:10.1042/bj20070823 · Cited by 28
“Interest in the application of iron chelators in the treatment of non iron overload diseases has also increased over the last 5 years with considerable effort being concentrated in two important fields, the treatment of cancer [4] and the treatment of neurodegeneration [5,6].”
BackgroundD'Acunto, C. W., Kaplánek, R., Gbelcová, H., Kejík, Z., Bříza, T., Vasina, L., Havlík, M., Ruml, T., & Král, V. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.02.084 · Cited by 26
Lukmantara, A. Y., Kalinowski, D. S., Kumar, N., & Richardson, D. R. (2013) · Organic & Biomolecular Chemistry · doi:10.1039/c3ob41109e · Cited by 28
Self-citationThe iron chelator Dp44mT does not protect myocytes against doxorubicin
Hasinoff, B. B., & Patel, D. (2009) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2009.05.007 · Cited by 25
Pandiarajan, D., & Ramesh, R. (2011) · Inorganic Chemistry Communications · doi:10.1016/j.inoche.2011.02.006 · Cited by 25
Conner, J. D., Medawala, W., Stephens, M. T., Morris, W., Deweese, J. E., Kent, P., Rice, J. J., Jiang, X., & Lisic, E. C. (2016) · Open Journal of Inorganic Chemistry · doi:10.4236/ojic.2016.62010 · Cited by 24
“In addition, α-N-heterocyclic thiosemicarbazones, with their N-N-S tridentate coordination backbone, are particularly well-known for their ability to chelate to biologically important transition metals, such as Cu(II) and Fe(II) [14]-[18].”
BackgroundDharmasivam, M., Kaya, B., Wijesinghe, T. P., Richardson, V., Harmer, J. R., Gonzálvez, M. A., Lewis, W., Azad, M. G., Bernhardt, P. V., & Richardson, D. R. (2023) · Chemical Science · doi:10.1039/d3sc05723b · Cited by 26
Self-citationAntioxidant and pro-oxidant in vitro evaluation of water-soluble food-related botanical extracts
Dorman, H. J. D., & Hiltunen, R. (2011) · Food Chemistry · doi:10.1016/j.foodchem.2011.06.017 · Cited by 23
Ahfad, N., Mohammadnezhad, G. S., Meghdadi, S., & Farrokhpour, H. (2019) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2019.117753 · Cited by 23
Sahni, S., Gillson, J., Park, K. C., Chiang, S., Leck, L. Y. W., Jansson, P. J., & Richardson, D. R. (2020) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2020.129625 · Cited by 23
Self-citationCytotoxic activity of expanded coordination bis-thiosemicarbazones and copper complexes thereof
Akladios, F. N., Andrew, S. D., & Parkinson, C. J. (2016) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-016-1390-7 · Cited by 24
A Colorimetric and Fluorescent Probe Based on Rhodamine B for Detection of Fe3+ and Cu2+ Ions
Yan, L., Xie, Y. H., & Li, J. (2019) · Journal of Fluorescence · doi:10.1007/s10895-019-02438-5 · Cited by 24
The iron-chelating drug triapine causes pronounced mitochondrial thiol redox stress
Myers, J. M., Antholine, W. E., Zielonka, J., & Myers, C. R. (2011) · Toxicology Letters · doi:10.1016/j.toxlet.2010.12.017 · Cited by 22
Elbayoumy, E., Shaker, M., Gaafar, M. M., Moawed, E. A., & Aboelnga, M. M. (2025) · Journal of Photochemistry and Photobiology A Chemistry · doi:10.1016/j.jphotochem.2025.116391 · Cited by 21
Lisic, E. C., Rand, V. G., Ngo, L. C., Kent, P., Rice, J., Gerlach, D. L., Papish, E. T., & Jiang, X. (2018) · Open Journal of Medicinal Chemistry · doi:10.4236/ojmc.2018.82004 · Cited by 21
“With their N-N-S tridentate coordination backbone, these α-N-heterocyclic thiosemicarbazones have been shown to chelate to biologically important transition metals, such as Cu(II) and Fe(II) [14] [15] [16] [17].”
BackgroundDual Sensing Performance of 1,2-Squaraine for the Colorimetric Detection of Fe3+ and Hg2+ Ions
Liu, X., Li, N., Xu, M., Jiang, C., Wang, J., Song, G., & Wang, Y. (2018) · Materials · doi:10.3390/ma11101998 · Cited by 19
Stariat, J., Kovaříková, P., Klimeš, J., Lovejoy, D. B., Kalinowski, D. S., & Richardson, D. R. (2008) · Journal of Chromatography B · doi:10.1016/j.jchromb.2008.11.044 · Cited by 20
Self-citationJakubek, M., Kejík, Z., Kaplánek, R., Antonyová, V., Hromádka, R., Šandriková, V., Sýkora, D., Pavel Martasek, E., & Král, V. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.02.034 · Cited by 19
“It should be mentioned that hydrazone-based chelators could possess potential toxicity, which could be complicated their possible applications [30].”
BackgroundSelyutina, O. Y., Kononova, P. A., Koshman, V. E., Shelepova, E. A., Azad, M. G., Afroz, R., Dharmasivam, M., Bernhardt, P. V., Polyakov, N. E., & Richardson, D. R. (2021) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2021.130078 · Cited by 19
“be implemented as part of the design of anti-cancer therapies [8,9].”
BackgroundSelf-citationRodríguez‐Lucena, D., Gaboriau, F., Rivault, F., Schalk, I. J., Lescoat, G., & Mislin, G. L. A. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.11.057 · Cited by 18
Strzelak, K., Rybkowska, N., Wiśniewska, A., & Koncki, R. (2017) · Analytica Chimica Acta · doi:10.1016/j.aca.2017.10.015 · Cited by 20
Wu, Y.-G., Wang, D.-B., Hu, J., Song, X., Xie, C., Ma, Z., & Xu, J. (2019) · Inorganic Chemistry Frontiers · doi:10.1039/c9qi00030e · Cited by 19
Sharma, S., Mehta, S. K., & Kansal, S. K. (2016) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2016.12.100 · Cited by 18
Metadata
- Authors
- Kalinowski, D. S., & Richardson, D. R.
- Affiliations
- The University of Sydney (AU)
- Corresponding author
- Richardson, Des R.
- Venue
- Chemical Research in Toxicology
- Publisher
- American Chemical Society (ACS)
- Published
- 2007-04-03
- Volume
- 20
- Issue
- 5
- Pages
- 715-720
- ISSN
- 0893-228X (ISSN-L)
- 1520-5010
- OpenAlex
- W2071434358
- Cited by
- 145
- References
- 15
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 9 · 2023: 6 · 2022: 6 · 2021: 7 · 2020: 9 · 2019: 9 · 2018: 10 · 2017: 6 · 2016: 11 · 2015: 9 · 2014: 4 · 2013: 3 · 2012: 7
- FWCI
- 6.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Chemical Research in Toxicology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Physical Sciences › Environmental Science › Health, Toxicology and Mutagenesis › Heavy Metal Exposure and Toxicity
- Keywords
- iron chelators, cancer chemotherapy, redox activity, hydrazone complexes, thiosemicarbazone complexes, iron chelation therapy
- MeSH terms
- Humans, Hydrazones, Iron Chelating Agents, Isoniazid, Pyridines, Pyridoxal, Structure-Activity Relationship, Thiosemicarbazones, Toxicology, Chelation Therapy, Iron Overload
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.